Literature DB >> 19528132

Model calibration in the continual reassessment method.

Shing M Lee1.   

Abstract

BACKGROUND: The continual reassessment method (CRM) is an adaptive model-based design used to estimate the maximum tolerated dose in dose finding clinical trials. A way to evaluate the sensitivity of a given CRM model including the functional form of the dose-toxicity curve, the prior distribution on the model parameter, and the initial guesses of toxicity probability at each dose is using indifference intervals. While the indifference interval technique provides a succinct summary of model sensitivity, there are infinitely many possible ways to specify the initial guesses of toxicity probability. In practice, these are generally specified by trial and error through extensive simulations.
METHODS: By using indifference intervals, the initial guesses used in the CRM can be selected by specifying a range of acceptable toxicity probabilities in addition to the target probability of toxicity. An algorithm is proposed for obtaining the indifference interval that maximizes the average percentage of correct selection across a set of scenarios of true probabilities of toxicity and providing a systematic approach for selecting initial guesses in a much less time-consuming manner than the trial-and-error method. The methods are compared in the context of two real CRM trials.
RESULTS: For both trials, the initial guesses selected by the proposed algorithm had similar operating characteristics as measured by percentage of correct selection, average absolute difference between the true probability of the dose selected and the target probability of toxicity, percentage treated at each dose and overall percentage of toxicity compared to the initial guesses used during the conduct of the trials which were obtained by trial and error through a time-consuming calibration process. The average percentage of correct selection for the scenarios considered were 61.5 and 62.0% in the lymphoma trial, and 62.9 and 64.0% in the stroke trial for the trial-and-error method versus the proposed approach. LIMITATIONS: We only present detailed results for the empiric dose toxicity curve, although the proposed methods are applicable for other dose-toxicity models such as the logistic.
CONCLUSIONS: The proposed method provides a fast and systematic approach for selecting initial guesses of probabilities of toxicity used in the CRM that are competitive to those obtained by trial and error through a time-consuming process, thus, simplifying the model calibration process for the CRM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19528132      PMCID: PMC2884971          DOI: 10.1177/1740774509105076

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  6 in total

1.  A simple technique to evaluate model sensitivity in the continual reassessment method.

Authors:  Ying Kuen Cheung; Rick Chappell
Journal:  Biometrics       Date:  2002-09       Impact factor: 2.571

2.  Continual reassessment method: a likelihood approach.

Authors:  J O'Quigley; L Z Shen
Journal:  Biometrics       Date:  1996-06       Impact factor: 2.571

3.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

4.  The continual reassessment method in cancer phase I clinical trials: a simulation study.

Authors:  S Chevret
Journal:  Stat Med       Date:  1993-06-30       Impact factor: 2.373

5.  Sequential designs for phase I clinical trials with late-onset toxicities.

Authors:  Y K Cheung; R Chappell
Journal:  Biometrics       Date:  2000-12       Impact factor: 2.571

6.  The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke.

Authors:  Mitchell S V Elkind; Ralph L Sacco; Robert B MacArthur; Daniel J Fink; Ellinor Peerschke; Howard Andrews; Greg Neils; Josh Stillman; Tania Corporan; Dana Leifer; Ken Cheung
Journal:  Int J Stroke       Date:  2008-08       Impact factor: 5.266

  6 in total
  72 in total

1.  Isotonic designs for phase I trials in partially ordered groups.

Authors:  Mark Conaway
Journal:  Clin Trials       Date:  2017-08-04       Impact factor: 2.486

2.  Performance of toxicity probability interval based designs in contrast to the continual reassessment method.

Authors:  Bethany Jablonski Horton; Nolan A Wages; Mark R Conaway
Journal:  Stat Med       Date:  2016-07-19       Impact factor: 2.373

3.  Flexible Phase I-II design for partially ordered regimens with application to therapeutic cancer vaccines.

Authors:  Nolan A Wages; Craig L Slingluff
Journal:  Stat Biosci       Date:  2019-06-04

4.  Integrating the escalation and dose expansion studies into a unified Phase I clinical trial.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  Contemp Clin Trials       Date:  2016-07-05       Impact factor: 2.226

5.  Continual reassessment method with multiple toxicity constraints.

Authors:  Shing M Lee; Bin Cheng; Ying Kuen Cheung
Journal:  Biostatistics       Date:  2010-09-28       Impact factor: 5.899

6.  Identifying a maximum tolerated contour in two-dimensional dose finding.

Authors:  Nolan A Wages
Journal:  Stat Med       Date:  2016-02-22       Impact factor: 2.373

7.  Calibration of prior variance in the Bayesian continual reassessment method.

Authors:  Shing M Lee; Ying Kuen Cheung
Journal:  Stat Med       Date:  2011-03-17       Impact factor: 2.373

8.  Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted Agents.

Authors:  Nolan A Wages; Craig A Portell; Michael E Williams; Mark R Conaway; Gina R Petroni
Journal:  Clin Cancer Res       Date:  2017-07-21       Impact factor: 12.531

9.  Evaluation of irrational dose assignment definitions using the continual reassessment method.

Authors:  Nolan A Wages; Evan Bagley
Journal:  Clin Trials       Date:  2019-09-23       Impact factor: 2.486

10.  Designs for phase I trials in ordered groups.

Authors:  Mark R Conaway; Nolan A Wages
Journal:  Stat Med       Date:  2016-09-14       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.